Authors

• A. Michael Lincoff (ORCID: https://orcid.org/0000-0001-8175-2121)
• Heather Powell (ORCID: https://orcid.org/0009-0003-1970-6361)
• Steven E. Nissen (ORCID: https://orcid.org/0000-0002-7231-6464)
• Jorge Plutzky (ORCID: https://orcid.org/0000-0002-7194-9876)
• Harold Edward Bays (ORCID: https://orcid.org/0000-0001-9912-1408)
• Stephen James Nicholls (ORCID: https://orcid.org/0000-0002-9668-4368)
• Danielle M. Brennan
• LeAnne T. Bloedon
• Lei Lei (ORCID: https://orcid.org/0009-0000-3826-9169)

Institutions

• Brigham and Women's Hospital (US)
• Cleveland Clinic (US)
• Harvard University (US)
• Esperion Therapeutics (United States) (US)
• Louisville Metabolic and Atherosclerosis Research Center (US)
• Monash University (AU)

Publication Details

Journal

Journal of the American Heart Association

Published

2025-02-08

DOI

https://doi.org/10.1161/jaha.124.037898

Citations

3

Primary Topic

Lipoproteins and Cardiovascular Health

Type

article

Field-Weighted Citation Impact

6.02

Funders

• Amgen
• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• AstraZeneca
• Sanofi
• FibroGen
• CSL Behring
• Regeneron Pharmaceuticals
• Anthera
• Kowa Company
• MyoKardia
• InfraRedx
• Novo Nordisk
• Akebia Therapeutics
• Silence Therapeutics
• Esperion Therapeutics